Abstract 3870
Background
The incidence of BCBM is increasing as a result of both improved diagnostic techniques and longer survival due to better treatment approaches. However, it is still a challenging situation occasioned by the poor responses to different standard therapies, representing an unmet medical need. Determining the molecular profile may be clinically relevant in order to improve the outcome of our patients (pts).
Methods
This is an observational retrospective study including BC-pts who had undergone surgery of BCBM in Hospital Clinic (Barcelona, Spain) between January 2000 and December 2017. RNA was isolated from FFPE tumor tissue and the expression of 55 BC-related genes was assessed on the nCounter. Median progression free survival (mPFS) and overall survival (mOS) were calculated using the Kaplan-Meier method. The association of the expression of each gene with mPFS was evaluated using univariate Cox-models. The same gene expression assay was tested BCBM-paired primary tumor samples.
Results
20 pts with resected BMBC were included. Median age at diagnosis of BCBM was 57.8years (y). mOS from diagnosis of BCBM was 20.22 months (range, 0.67-64.50months). The intrinsic subtype distribution was 45% Basal-like, 20% HER2-enriched (HER2-E), 10% Luminal A, 20% Luminal B and 5% Normal-like. High expression of ESR1and PGR (determined as above the median) and low expression of MKI67were related with better mOS (p = 0.008, p = 0.038 and p = 0.0165). 9 matched-paired samples of primary BC and BCBM were analyzed and 4 (44.4%) PAM50 discordances (2 Luminal B shifted to Luminal A, 1 Normal-like to Basal-like and 1 HER2-E to Luminal B) were observed. Finally, down-regulation of CD8Aand PDL1expression between primary and BCBM (p = 0.0234 and p = 0.0367, respectively) was observed.
Conclusions
Non-luminal intrinsic subtypes are more prevalent in resected BCBM, and gene expression might predict OS. Our data suggest that BCBM can elude the immune surveillance through downregulation of immune genes leading to an immunosuppressed environment. Our analysis shows the value of analyzing gene expression both by cancer subtype and metastatic origin, but further characterization is needed.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute, Barcelona, Spain.
Funding
Fundación Científica Asociación Española Contra el Cáncer (PRÁCTICAS AECC CURSO ACADÉMICO 2018 to M.M-L).
Disclosure
M. Vidal: Speaker Bureau / Expert testimony: Roche; Speaker Bureau / Expert testimony: Daiichi Sankyo; Speaker Bureau / Expert testimony: Novartis. M. Muñoz: Travel / Accommodation / Expenses: Roche. A. Prat: Advisory / Consultancy: Nanostring Tech. All other authors have declared no conflicts of interest.
Resources from the same session
733 - Clinical experience: ramucirumab with FOLFIRI/XELIRI as a second line for patients with metastatic gastric cancer
Presenter: Tatiana Titova
Session: Poster Display session 2
Resources:
Abstract
2186 - Efficacy and safety of apatinib for the treatment of AFP-producing gastric cancer
Presenter: Ningning Li
Session: Poster Display session 2
Resources:
Abstract
3172 - Apatinib in combination with docetaxol and S1 chemotherapy in the first line treatment of metastatic gastric cancer
Presenter: Ling Xia
Session: Poster Display session 2
Resources:
Abstract
3982 - Parameters of local cellular immunity in metastatic gastric cancer
Presenter: Aleksandr Sagakyants
Session: Poster Display session 2
Resources:
Abstract
5102 - Germline pathogenic mutations in Chinese patients with gastric cancer identified by next-generation sequencing (NGS)
Presenter: Xiaotian Zhang
Session: Poster Display session 2
Resources:
Abstract
5012 - Inhibition of the PI3K pathway in HER2-positive gastric cancer
Presenter: Sinead Toomey
Session: Poster Display session 2
Resources:
Abstract
4803 - Investigation on gastric cancer susceptibility genes in Chinese early-onset diffuse gastric cancer
Presenter: Yi Feng
Session: Poster Display session 2
Resources:
Abstract
4778 - A correlation analysis between survival rate and the characteristic gene of gastric cancer based on bioinformatics analysis
Presenter: Yi-wen Zhang
Session: Poster Display session 2
Resources:
Abstract
4805 - Phase I study of apatinib combined with POF (paclitaxel plus FOLFOX) in patients (pts) with treatment-naïve advanced gastric cancer (TNAGC)
Presenter: Rongbo LIN
Session: Poster Display session 2
Resources:
Abstract
3248 - Second-line palliative systemic treatment for synchronous metastatic esophagogastric cancer: a population-based study
Presenter: Willemieke Dijksterhuis
Session: Poster Display session 2
Resources:
Abstract